Drug Profile
Volixibat - Mirum Pharmaceuticals
Alternative Names: LUM-002; SAR-548304; SHP-626; Volixibat - Takeda; Volixibat potassiumLatest Information Update: 20 Nov 2023
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Mirum Pharmaceuticals; Sanofi; Shire
- Class Anti-inflammatories; Antihyperlipidaemics; Benzothiepins; Hepatoprotectants; Urea compounds
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Primary biliary cirrhosis
- Phase II Intrahepatic cholestasis; Primary sclerosing cholangitis
- No development reported Cholestasis
- Discontinued Hypercholesterolaemia; Non-alcoholic steatohepatitis
Most Recent Events
- 13 Nov 2023 Efficacy and adverse events data from phase IIa/IIb OHANA trial in Intrahepatic cholestasis released by Mirum Pharmaceuticals
- 10 Nov 2023 Efficacy and adverse event data from the phase IIa/IIb OHANA trial in Intrahepatic cholestasis presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 29 Nov 2022 Mirum Pharmaceuticals discontinues phase IIa/IIb OHANA trial in Intrahepatic cholestasis in US, New Zealand and the UK due to enrollment feasibility